Effects of an oral contraceptive containing estradiol valerate and dienogest on circulating androgen levels and acne in young patients with PCOS: An observational preliminary study

Gynecological Endocrinology

Volumn 29, Issue 12, 2013, Pages 1048-1050

  Di Carlo, Costantino ^a   Gargano, Virginia ^a   Sparice, Stefania ^a   Tommaselli, Giovanni A ^a   Bifulco, Giuseppe ^a   Nappi, Carmine ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Acne; Dienogest; Estradiol valerate; PCOS

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; DIENOGEST PLUS ESTRADIOL VALERATE; SEX HORMONE BINDING GLOBULIN; STEROID 5ALPHA REDUCTASE; TESTOSTERONE;

ACNE; ADOLESCENT; ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HUMAN; OBSERVATIONAL STUDY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION;

ACNE VULGARIS; ADOLESCENT; ANDROGENS; CONTRACEPTIVES, ORAL, HORMONAL; ESTRADIOL; FEMALE; HUMANS; LONGITUDINAL STUDIES; NANDROLONE; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDIES; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; YOUNG ADULT;

EID: 84887244138     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2013.831834     Document Type: Article

References (25)

1. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853-61.
2. De Leo V, La Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2003; 24: 633-67.
3. Oláh KS. The modern management of hirsutism. Rev Gynaecol Practice 2004;4:211-20.
4. The Endocrine Society's Clinical Guidelines. Evaluation & Treatment of Hirsutism in Premenopausal Women: an Endocrine Society Clinical Practice Guideline. J Clin Endocr Metab 2008;93: 1105-20.
5. Murphy AA, Cropp CS, Smith BS, et al. Effect of low-dose oral contraceptive on gonadotropins, androgens, and sex hormone binding globulin in non-hirsute women. Fertil Steril 1990;53:35-9.
6. van der Vange N, Blankenstein MA, Kloosterboer HJ, et al. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception 1990;41:345-52.
7. Jung-Hoffmann C, Kuhl H. Divergent effects of two low-dose oral contraceptives on sex hormone-binding globulin and free testosterone. Am J Obstet Gynecol 1987;156:199-203.
8. Azziz R, Gay F. The treatment of hyperandrogenism with oral contraceptives. Semin Reprod Endocrinol 1989;7:246-54.
9. Dewis P, Petsos P, Newman M, Anderson DC. The treatment of hirsutism with a combination of desogestrel and ethinyl oestradiol. Clin Endocrinol 1985;22:29-36.
10. Azziz R. The evaluation and management of hirsutism. Obstet Gynecol 2003;101:995-1007.
11. Alsina JC. After 50 years of ethinylestradiol, another oestrogen in combined oral contraceptives. Eur J Contracept Reprod Health Care 2010;15:1-3.
12. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2008;61:151-7.
13. Sitruk-Ware R, Nath A. The use of newer progestins for contraception. Contraception 2010;82:410-7.
14. Bitzer J. The importance of antiandrogenicity of progestogens. Gynaecol Forum 2009;14:21-3.
15. Mueck AO, Seeger H. Pharmacology of dienogest. Gynaecol Forum 2009;14:9-12.
16. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81:19-25.
17. Ramli R, Malik AS, Hani AFM, Jamil A. Acne analysis, grading and computational assessment methods: an overview. Skin Res Technol 2012;18:1-14.
18. Lasek RJ, Chren MM. Acne vulgaris and the quality of life of adult dermatology patients. Arch Dermatol 1998;134:454-8.
19. Palombo-Kinne E, Schellschmidt I, Schumacher U, Gräser T. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate. Contraception 2009;79:282-99.
20. van Vloten WA, van Haselen CW, van Zuuren EJ, et al. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002;69:2-15.
21. Caruso S, Agnello C, Romano M, et al. Preliminary study on the effect of four-phasic estradiol valerate and dienogest (E2V/DNG) oral contraceptive on the quality of sexual life. J Sex Med 2011;8: 2841-50.
22. Guida M, Bifulco G, Di Spiezio Sardo A, et al. Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill. Int J Womens Health 2010;2: 279-90.
23. Wiegratz I, Jung-Hoffmann C, Kuhl H. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception 1995;51:341-6.
24. Arrington EA, Patel NS, Gerancher K, Feldman SR. Combined oral contraceptives for the treatment of acne: a practical guide. Cutis 2012;90:83-90.
25. Del Marmol V, Teichmann A, Gertsen K. The role of combined oral contraceptives in the management of acne and sebborhea. Eur J Contracep Reprod Health Care 2004;9:107-24.